Faron Pharmaceuticals - Innovative medical solutions (Part 2)

Excluded from BEXMAB if:
“Allogeneic transplantation less than 6 months prior screening.”
Doesn’t the BEAM study push BEX for precisely that post-transplant state?
Is there a significant dosage difference or some other risk? Explain, wise ones!

2 Likes